# EDGAR Filing Document

**Accession Number:** 0001611842
**File Stem:** 0001213900-25-121938
**Filing Date:** 2025-12
**Character Count:** 11768
**Document Hash:** a794727bfb1f8db6714f20add29bedf0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-121938.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001213900-25-121938

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251216

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PolyPid Ltd.
- **CENTRAL INDEX KEY:** 0001611842
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38428
- **FILM NUMBER:** 251573445

**BUSINESS ADDRESS:**
- **STREET 1:** 18 HASIVIM STREET
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4959376
- **BUSINESS PHONE:** 972-74-7195700

**MAIL ADDRESS:**
- **STREET 1:** 18 HASIVIM STREET
- **CITY:** PETACH TIKVA
- **STATE:** L3
- **ZIP:** 4959376

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of: December 2025 (Report No. 2)**

**Commission File Number: 001-38428**

**PolyPid Ltd.**

**(Translation of registrant's name into English)**

**18 Hasivim Street**

**Petach Tikva 495376, Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**CONTENTS**

On December 16, 2025, PolyPid Ltd. (the "Company") announced the appointment of Brooke Story as a director and chairman to its Board of Directors (the "Board"), effective December 11, 2025.

Ms. Story, age 54, has lead the separation and integration management office at BD (Becton, Dickinson and Company) (NYSE:BDX) ("BD") since June 2024. She was Worldwide President, Surgery, at BD from July 2023 to March 2024, and Worldwide President, Integrated Diagnostic Solutions, at BD from April 2021 to July 2023. From December 2018 to April 2021, Ms. Story worked as President, Pelvic Health and Gastric Therapies, at Medtronic plc (NYSE: MDT) ("Medtronic"). Prior to that, Ms. Story held various positions at Medtronic. Ms. Story has been serving as a director at LivaNova, PLC (Nasdaq: LIVN) since September 2022. She also served as a director at Sigilon Therapeutics, Inc. (Nasdaq: STGX) from June 2021 to September 2022. Ms. Story holds a B.S. degree from the University of Tennessee, Knoxville in Knoxville, Tennessee, United States, and earned an M.B.A. from the University of Michigan in Ann Arbor, Michigan, United States.

The Board concluded that Ms. Story is qualified to serve as a director and is independent under the rules of the Nasdaq Stock Market. The Company expects to propose Ms. Story's compensation for her service on the Board for approval by the Company's shareholders at an upcoming shareholder meeting. The Company expects to enter into its standard indemnification agreement with Ms. Story, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. Ms. Story is not a party to any transactions that are disclosable under Item 7.B of Form 20-F.

The Company's press release dated December 16, 2025, announcing Ms. Story's appointment is attached hereto as Exhibit 99.1.

The Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's registration statements on Form F-3 (File No. [333-276826](http://www.sec.gov/Archives/edgar/data/1611842/000121390024009108/ea192572-f3_polypidltd.htm), File No. [333-280658](http://www.sec.gov/Archives/edgar/data/1611842/000121390024058595/ea0208115-f3_polypidltd.htm), File No. [333-281863](http://www.sec.gov/Archives/edgar/data/1611842/000121390024074508/ea0212801-f3_polypidltd.htm), File No. [333-284376](http://www.sec.gov/Archives/edgar/data/1611842/000121390025004999/ea0227827-f3_polypid.htm) and File No. [333-289034](http://www.sec.gov/Archives/edgar/data/1611842/000121390025068692/ea0250584-f3_polypid.htm)) and Form S-8 (File No. [333-239517](http://www.sec.gov/Archives/edgar/data/1611842/000110465920077735/tm209265d11_s8.htm), File No. [333-271060](http://www.sec.gov/Archives/edgar/data/1611842/000121390023025649/ea176190-s8_polypid.htm), File No. [333-277703](http://www.sec.gov/Archives/edgar/data/1611842/000121390024020445/ea0201047-s8_polypid.htm), File No. [333-280662](http://www.sec.gov/Archives/edgar/data/1611842/000121390024058604/ea0208116-s8_polypid.htm) and File No. [333-289570](http://www.sec.gov/Archives/edgar/data/1611842/000121390025075646/ea0252816-s8_polypid.htm)) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| 99.1 | [Press release issued by PolyPid Ltd. on December 16, 2025, titled "PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors."](ea026984101ex99-1_polypid.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **POLYPID LTD.** | **POLYPID LTD.** | **POLYPID LTD.** |
| Date: December 16, 2025 | By: | /s/ Dikla Czaczkes Akselbrad | /s/ Dikla Czaczkes Akselbrad |
|  |  | Name: | Dikla Czaczkes Akselbrad |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors**

 

*Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead<br> of D-PLEX<sub>100</sub> New Drug Application Submission* 

**PETACH TIKVA, Israel – December 16, 2025** – PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025.

"Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transforming our clinical success into a commercial reality."

Ms. Story brings more than 25 years of MedTech leadership, including senior positions at Becton, Dickinson and Company ("BD") and Medtronic PLC. As former Worldwide President, Surgery at BD, she managed Profit and Loss (P&L) for the hernia, tissue repair, and high-stakes infection prevention portfolios. She has extensive experience leading mergers and acquisitions as well as licensing transactions, currently serving as an Integration Lead for global integrations, and managing P&L performance while driving strategic results.

"I am honored to join PolyPid at this pivotal stage in the Company's development," said Ms. Story. "I look forward to supporting the team as it leverages its delivery platform to address critical, high-cost needs in surgical infection prevention, creating a clear opportunity to build significant enterprise value and bring potentially transformative solutions to the healthcare market."

Alongside her new role with PolyPid, Ms. Story currently serves as a non-executive director on the Board of LivaNova PLC. (Nasdaq: LIVN). She previously served on the Board of Sigilon Therapeutics, Inc. (Nasdaq: SGTX) and as Board observer for Avation Medical, Inc. She holds a Bachelor of Science in Engineering from the University of Tennessee and an MBA from the University of Michigan.

**About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX**<sub>100</sub>**, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

**Forward-looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expected NDA submission of D-PLEX**<sub>100 </sub>**and the timing thereof, the Company's ability to build enterprise value, and the Company's ability to bring transformative solutions to the healthcare market. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

**Company Contact:**

PolyPid Ltd.<br> Ori Warshavsky<br> 908-858-5995<br> IR@Polypid.com

**Investor Relations Contact:**

Arx Investor Relations<br> North American Equities Desk<br> polypid@arxhq.com